Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19 Patients: An Observational Study
et al., Preprints, doi:10.20944/preprints202005.0057.v1, May 2020
HCQ for COVID-19
1st treatment shown to reduce risk in
March 2020, now with p < 0.00000000001 from 424 studies, used in 59 countries.
No treatment is 100% effective. Protocols
combine treatments.
6,300+ studies for
210+ treatments. c19early.org
|
166 patients hospitalised with COVID-19, HCQ increased survival 1.4 - 1.8 times when patients admitted in early stages. Early is relative to hospital admission here - all patients were in relatively serious condition.
|
risk of death, 55.1% lower, RR 0.45, p = 0.002, treatment 27 of 123 (22.0%), control 21 of 43 (48.8%), NNT 3.7.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Membrillo de Novales et al., 5 May 2020, retrospective, Spain, preprint, 19 authors, average treatment delay 7.0 days.
Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19 Patients: An Observational Study
doi:10.20944/preprints202005.0057.v2
Hydroxychloroquine has shown in vitro activity against SARS-CoV-2. Here we present an observational study. We analysed data from 164 patients admitted to our hospital diagnosed with COVID-19. Hydroxychloroquine treatment was associated with an increase in the mean cumulative survival.
References
Bersanelli, Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors, Immunotherapy, doi:10.2217/imt-2020-0067
Cao, Wang, Wen, Liu, Wang et al., A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19, doi:10.1056/NEJMoa2001282
Gao, Tian, Yang, Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105949
Huang, Tang, Pang, Li, Ma et al., Treating COVID-19 with Chloroquine, J Mol Cell Biol, doi:10.1093/jmcb/mjaa014
Keyaerts, Vijgen, Maes, Neyts, Ranst et al., In vitro inhibition of severe acuterespiratory syndrome coronavirus by chloroquine, Biochem Biophys Res Commun
Loutfy, Blatt, Siminovitch, Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study, JAMA, doi:10.1001/jama.290.2%204.3222
Medina Segovia, Mata, Suero, Jané, Vicente Saenz et al., Internal Medicine Department: María Jesús Sánchez Carrillo
Morgenstern, Michaelis, Baer, Doerr, Cinatl, Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines, Biochem Biophys Res Commun, doi:10.1016/j.bbrc.2004.11.128
Ramos Meca, Portales, Ángeles, Mayor, Pérez Amarilla et al., Emergency Department: Preprints
Ruiz, Coca Benito, Cano Izquierdo, Lourdes Rojas, Bueno et al., General and Digestive Surgery Department: Oscar Marqueta García
Thevarajan, Nguyen, Koutsakos, Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19, Nat Med, doi:10.1038/s41591-020-0819-2
Turner, Felton, Kosak, Kelsey, Meschievitz, Prevention of experimental coronavirus colds with intranasal alpha-2b interferon, J Infect Dis, doi:10.1093/infdis/154.3.443
Vincent, Bergeron, Benjannet, Erickson, Rollin et al., Chloroquine is a potent inhibitor of SARS coronavirus infection and spread, Virol J
Wang, Xu, Gao, Lu, Han et al., Detection of SARS-CoV-2 in different types of clinical specimens, JAMA
Yao, Ye, Zhang, Cui, Huang et al., Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clin Infect Dis, doi:10.1093/cid/ciaa237
Zhang, Song, Tong, Fei, Guo et al., First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab, Blood Adv, doi:10.1182/bloodadvances.2020001907
DOI record:
{
"DOI": "10.20944/preprints202005.0057.v1",
"URL": "http://dx.doi.org/10.20944/preprints202005.0057.v1",
"abstract": "<jats:p>Background: There is no treatment proven effective against COVID-19. Several drugs with in vitro potential against SARS-CoV-2 virus have been proposed. Hydroxychloroquine has in vitro anti-viral and immunomodulatory activity, but there is no current clinical evidence of its effectiveness changing the outcome of the disease. Methods: We enrolled all 18-85 years old inpatients from Central Defense Hospital &ldquo;G&oacute;mez Ulla&rdquo;, Madrid, Spain, who were hospitalised for COVID-19 and had a definitive outcome (dead or discharged). We used a statistical survival analysis to detect treatment differences associated with in-hospital death. Results: We analysed first 220 medical records. 166 patients met the inclusion criteria. 48,8 % of patients not treated with HCQ died, 22% of those treated with hydroxychloroquine (p=0,002). According to clinical picture at admission, hydroxychloroquine increased the mean cumulative survival in all groups from 1,4 to 1,8 times. This difference was statistically significant in the mild group. Conclusions: in a cohort of 166 patients from 18 to 85 years hospitalised with COVID-19, hydroxychloroquine treatment with 800mg added loading dose increased survival when patients were admitted in early stages of the disease. There was a non-statistically significant trend towards survival in all groups, which will have to be clarified in subsequent studies.</jats:p>",
"accepted": {
"date-parts": [
[
2020,
5,
2
]
]
},
"author": [
{
"affiliation": [],
"family": "Membrillo de Novales",
"given": "Francisco Javier",
"sequence": "first"
},
{
"affiliation": [],
"family": "Ramírez-Olivencia",
"given": "Germán",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Estébanez",
"given": "Miriam",
"sequence": "additional"
},
{
"affiliation": [],
"family": "de Dios",
"given": "Begoña",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Herrero",
"given": "María Dolores",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Mata",
"given": "Tatiana",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Borobia",
"given": "Alberto M.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Gutiérrez",
"given": "Carlos",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Simón",
"given": "María",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Ochoa",
"given": "Ana",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Martínez",
"given": "Yolanda",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Aguirre",
"given": "Alejandro",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Alcántara",
"given": "Francisco de Asís",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Fernández-González",
"given": "Pablo",
"sequence": "additional"
},
{
"affiliation": [],
"family": "López",
"given": "Elena",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Campos",
"given": "Sergio",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Navarro",
"given": "María",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Ballester",
"given": "Lucía Elena",
"sequence": "additional"
}
],
"container-title": [],
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2020,
5,
7
]
],
"date-time": "2020-05-07T03:53:07Z",
"timestamp": 1588823587000
},
"deposited": {
"date-parts": [
[
2020,
5,
11
]
],
"date-time": "2020-05-11T10:44:34Z",
"timestamp": 1589193874000
},
"group-title": "MEDICINE & PHARMACOLOGY",
"indexed": {
"date-parts": [
[
2024,
3,
3
]
],
"date-time": "2024-03-03T11:38:36Z",
"timestamp": 1709465916640
},
"is-referenced-by-count": 13,
"issued": {
"date-parts": [
[
2020,
5,
5
]
]
},
"license": [
{
"URL": "http://creativecommons.org/licenses/by/4.0",
"content-version": "unspecified",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2020,
5,
5
]
],
"date-time": "2020-05-05T00:00:00Z",
"timestamp": 1588636800000
}
}
],
"member": "1968",
"original-title": [],
"posted": {
"date-parts": [
[
2020,
5,
5
]
]
},
"prefix": "10.20944",
"published": {
"date-parts": [
[
2020,
5,
5
]
]
},
"publisher": "MDPI AG",
"reference-count": 0,
"references-count": 0,
"relation": {
"has-version": [
{
"asserted-by": "object",
"id": "10.20944/preprints202005.0057.v2",
"id-type": "doi"
}
],
"is-version-of": [
{
"asserted-by": "subject",
"id": "10.20944/preprints202005.0057.v2",
"id-type": "doi"
}
]
},
"resource": {
"primary": {
"URL": "https://www.preprints.org/manuscript/202005.0057/v1"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subtitle": [],
"subtype": "preprint",
"title": "Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19 Patients: An Observational Study",
"type": "posted-content"
}
Late treatment
is less effective
is less effective
